Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0042109 (urticaria)
 6,569 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A prospective study of the natural history of acute hepatitis B was performed in 38 patients. Fatigue started median 4 weeks, abdominal symptoms median 3 weeks and signs of cholestasis median 2.5 weeks before peak SGPT values were reached. Extrahepatic manifestations occurred throughout the prodromal stage, the presence of arthropathy, urticaria or skin rashes was not related to the biochemical severity of liver disease. The higher the the maximal values of serum bilirubin and/or the older the patient, the longer the period of bilirubin elevation; a maximal bilirubin elevation less than 20 X the upper limit of normal was associated with normalisation of serum bilirubin within 6 weeks. No such correlations were found between the height of serum glutamic pyruvic transaminase, alkaline phosphatase, thymol turbidity and cholesterol levels and the subsequent duration of their abnormality. The elevation of alkaline phosphatase as well as the abdominal complaints might partly be caused by gastro-intestinal involvement. Immobilisation before peak SGPT was attained was associated with normalisation of serum glutamic pyruvic transaminase levels within 8 weeks after peak levels. 37 patients recovered completely. In one HBs-antigenemia and slight SGPT elevation persisted. Long term follow up was possible in 33 patients for 4 to 7 years, median 5 years.
 ...
PMID:Natural history of acute hepatitis B in previously healthy patients: A prospective study. 27 Aug 89

This is a clinical description of an unusual arthropathy in 2 members of a family with familial cold urticaria. Relevant investigations, X-ray illustrations and the family pedigree are presented. The nature of the arthropathy and its possible relationship to other arthropathies is discussed.
 ...
PMID:Arthropathy associated with familial cold urticaria. 84 33

We have presented a case of atopic dermatitis associated with Giardia lamblia infection, which has not been previously described. Review of the world literature shows an association between giardiasis and urticaria. Other allergic phenomena, such as angioedema and possibly arthropathy, also might be associated with this infection. When confronted with these clinical problems, giardiasis should be included in the differential diagnosis. As these complications respond to specific therapy, identification of this organism as its cause can be particularly rewarding.
 ...
PMID:Dermatologic manifestations of giardiasis. 149

The new antiprotease hemosorbent Ovosorb was tested during the performance of blood perfusion (BP) used as part of multimodality treatment of 11 patients. Of these, 2 presented with disseminated psoriasis, 3 with arthropathic psoriasis, 1 with psoriatic erythrodermia, 4 with atopic dermatitis, and 1 with recurrent urticaria. BP with the use of the hemosorbent Ovosorb produced the highest effect in patients with atopic dermatitis, psoriatic erythrodermia and recurrent urticaria; BP with Ovosorb was less effective in disseminated psoriasis. The clinical effect was lacking in patients with arthropathic psoriasis. Ovosorb possesses remarkable detoxifying properties, good blood compatibility; it does not provoke any complications in patients with different forms of psoriasis, atopic dermatitis, and urticaria.
 ...
PMID:[The initial clinical experience of using Ovosorb antiprotease hemosorbent in the combined treatment of dermatoses]. 180 13

Cytokines such as Interleukin-1 (IL-1) are important modulators of the cell-mediated immune response and play a paramount role in inflammatory autoimmune disease. We report on preliminary clinical experiences with a new, tricyclic substance [( 10-Methoxy-4H-benzo[4,5]cyclo-hepta-[1,2-b]thiophene-4- ylidene]acetic acid, MW 284), which inhibits the release of interleukin-1 alpha and -beta from cultured murine macrophages or human mononuclear cells. The study included 12 patients (rheumatoid arthritis, n = 9; hemochromatotic arthropathy, n = 1; psoriatic arthropathy, n = 1; seronegative spondylarthropathy, n = 1). Eight patients were treated for a total of 8 weeks, receiving a median dose of 800 mg/d of the substance. Due to significant clinical benefits, two patients continued for a total of six months. Administration of the drug was discontinued in two patients because of severe urticaria and lack of compliance, respectively. Four out of 10 patients showed clinical improvement according to Ritchie-Index, pain score, ESR and CRP. Side effects were diffuse gastrointestinal symptoms (4/12), temporary impairment of liver function (4/12) and allergic skin reactions (3/12).
 ...
PMID:[Initial clinical experiences in the treatment of chronic polyarthritis with a new monokine release inhibitor]. 267 92

An erythematous, burning papular eruption, constitutional symptoms, fever, and arthropathy developed in a 65-year-old patient after cold exposure. Involvement of other family members occurred in an autosomal dominant pattern. Histopathologic examination of a biopsy specimen revealed telangiectasia and primarily neutrophilic perivascular inflammation, consistent with earlier biopsy reports of this syndrome. Although previously called "familial cold urticaria," this disease is not characterized by urticaria and may be best descriptively termed, "familial polymorphous cold eruption."
 ...
PMID:Familial polymorphous cold eruption. 722 87

Quinolones, elective drugs for Pseudomonas aeruginosa (P. aeruginosa) pulmonary infections in Cystic Fibrosis (C.F.) patients, are controversially administered in prepuberal age for their arthropathic toxicity. We report the result of retrospective study on the use of quinolones in a group of 43 CF patients. The patients were divided into two groups: below 18 years (22 pts.) and over 18 (21 pts.). All patients were evaluated clinically with the scoring system Shwachman and Kulczyk. Ciprofloxacin and Ofloxacin (15/20 mg/kg/die) were administered. In 11.6% of the patients, all belonging to the second group, side effects, such as urticaria, tongue oedema, foreskin erythema, generalised erythema and itch, were described. No side effect has been reported in the patients below 18 years. Two patients complained knee arthralgias not related to the quinolones administration: in fact in the first case the demineralisation seemed to be responsible of the arthralgia, while in the second case an immunological disorder (ANA+, ICC+) should be involved in the pathogenesis of arthritis. Height velocity evaluation showed the same slowering of the CF untreated patients. In conclusion, our study confirms that quinolones use in indicated in severe and infective complications of CF on the basis of their efficacy, safety and their slight adverse effects similar to those of other potent antibiotic. Moreover our results confirm that no quinolone-induced cartilage toxicity is present in CF patients.
 ...
PMID:[Use of quinolones in the treatment of Pseudomonas aeruginosa infections in children with cystic fibrosis]. 773 28

Muckle-Wells syndrome (MWS) is a rare condition characterized by urticaria, arthralgias, deafness and amyloid nephropathy. The arthropathy is poorly documented. We describe the arthropathy occurring in four cases of MWS and discuss the management. Each patient developed recurrent bouts of transient synovitis. One patient developed a persistent sterile pyoarthrosis.
 ...
PMID:The arthropathy of the Muckle-Wells syndrome. 800 Jul 53

Chronic infantile neurological cutaneous and articular (CINCA) syndrome is a severe chronic inflammatory disease of early onset, characterized by cutaneous symptoms, central-nervous-system involvement, and arthropathy. In the present study, we report, in seven unrelated patients with CINCA syndrome, distinct missense mutations within the nucleotide-binding site of CIAS1, a gene encoding cryopyrin and previously shown to cause Muckle-Wells syndrome and familial cold urticaria. Because of the severe cartilage overgrowth observed in some patients with CINCA syndrome and the implications of polymorphonuclear cell infiltration in the cutaneous and neurological manifestations of this syndrome, the tissue-specific expression of CIAS1 was evaluated. A high level of expression of CIAS1 was found to be restricted to polymorphonuclear cells and chondrocytes. These findings demonstrate that CIAS1 missense mutations can result in distinct phenotypes with only a few overlapping symptoms and suggest that this gene may function as a potential inducer of apoptosis.
 ...
PMID:Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. 1203 15

Tumor necrosis factor receptor-associated periodic syndrome (TRAPS) is an autosomal dominant inherited condition of periodic fever and pain. Most patients are of northern European descent. The attacks manifest as fever and pain in the joints, abdomen, muscles, skin, or eyes, with variations across patients. An acute-phase response occurs during the attacks. Patients with TRAPS are at risk for AA amyloidosis, the most common targets being the kidneys and liver. Soluble TNFRSF1A is usually low between the attacks and may be normal during the attacks, when TNF levels are high. TNFRSF1A is found in abnormally high numbers on leukocyte cell membranes. TRAPS is the first condition for which naturally occurring mutations in a TNF receptor were found; the mutations affect the soluble TNFRSF1A gene in the 12p13 region. In some patients, the pathogenesis involves defective TNFRSF1A shedding from cell membranes in response to a given stimulus. Thus, TRAPS is a model for a novel pathogenic concept characterized by failure to shed a cytokine receptor. This review compares TRAPS to other inherited periodic febrile conditions, namely, familial Mediterranean fever, Muckle-Wells syndrome, cold urticaria, and hyper-IgD syndrome. The place of TRAPS relative to other intermittent systemic joint diseases is discussed. Colchicine neither relieves nor prevents the attacks, whereas oral glucocorticoid therapy is effective when used in dosages greater than 20 mg/day. The pathogenic hypothesis involving defective TNFRSF1A shedding suggests that medications targeting TNF may be effective in TRAPS.
 ...
PMID:Tumor necrosis factor receptor-associated periodic syndrome (TRAPS): definition, semiology, prognosis, pathogenesis, treatment, and place relative to other periodic joint diseases. 1528 52


1 2 Next >>